Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥6,210 JPY
Change Today -200.00 / -3.12%
Volume 955.0K
As of 2:00 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

yakult honsha co ltd (2267) Snapshot

Open
¥6,290
Previous Close
¥6,410
Day High
¥6,400
Day Low
¥6,150
52 Week High
04/9/15 - ¥9,030
52 Week Low
10/17/14 - ¥5,090
Market Cap
1.1T
Average Volume 10 Days
801.4K
EPS TTM
¥172.69
Shares Outstanding
175.9M
EX-Date
09/28/15
P/E TM
36.0x
Dividend
¥30.00
Dividend Yield
0.40%
Current Stock Chart for YAKULT HONSHA CO LTD (2267)

Related News

No related news articles were found.

yakult honsha co ltd (2267) Related Businessweek News

View More BusinessWeek News

yakult honsha co ltd (2267) Details

Yakult Honsha Co., Ltd., a probiotics company, primarily manufactures and sells food and beverage products. It operates through Food and Beverages (Japan), Food and Beverages (The Americas), Food and Beverages (Asia and Oceania), Food and Beverages (Europe), Pharmaceuticals, and Others. The company offers food and beverages products comprising fermented milk drinks, juices, noodles, etc. through its home delivery and retail store channels. It also provides pharmaceutical products, including Elplat, a cancer chemotherapeutic agent for the treatment of colorectal cancer; Levofolinate Yakult, an activated folic acid drug; Gemcitabine Yakult, an antineoplastic antimetabolite; recombinant DNA G-CSF chemotherapy preparation Neu-up; Imatinib yakult, a generic antineoplastic drug; and Campto, an active pharmaceutical ingredient. The company is also developing Elplat for gastric cancer; PR610, a hypoxia activated pro drug; Perifosine, a PI3K/Akt inhibitor; Resminostat, an oral HDAC inhibitor; LIV-2008, which are humanized monoclonal anticancer antibodies; antibody biosimilars; and Zoledronic acid intravenous drip, a generic drug for bone lesions. In addition, it offers cosmetics and skin care products under the Parabio, Revecy, and Revecy White brand names; and BECYCLE Lift Repair Essence, which adds firmness and resilience to the skin, as well as operates and manages the Tokyo Yakult Swallows, a professional baseball team. The company was founded in 1935 and is headquartered in Tokyo, Japan.

22,036 Employees
Last Reported Date: 06/25/15
Founded in 1935

yakult honsha co ltd (2267) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥150.0M
Compensation as of Fiscal Year 2015.

yakult honsha co ltd (2267) Key Developments

Yakult Honsha Co. Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Yakult Honsha Co. Ltd. announced consolidated and non-consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, on consolidated the company reported net sales of JPY 92,858 million compared to JPY 86,379 million a year ago. Operating income was JPY 10,099 million compared to JPY 5,903 million a year ago. Ordinary income was JPY 12,879 million compared to JPY 8,293 million a year ago. Income before income taxes and minority interests was JPY 13,115 million compared to JPY 8,260 million a year ago. Profit attributable to owners of parent company was JPY 7,938 million compared to JPY 4,451 million a year ago. For the quarter, on non-consolidated the company reported net sales of JPY 46,267 million compared to JPY 43,734 million a year ago. Operating income was JPY 1,657 million compared to operating loss of JPY 1,025 million a year ago. Ordinary income was JPY 4,811 million compared to JPY 1,877 million a year ago. Net income was JPY 3,920 million compared to JPY 1,488 million a year ago.

Yakult Honsha Co. Ltd. to Report Q1, 2016 Results on Jul 28, 2015

Yakult Honsha Co. Ltd. announced that they will report Q1, 2016 results on Jul 28, 2015

Yakult Honsha Co. Ltd., Q1 2016 Earnings Call, Jul 28, 2015

Yakult Honsha Co. Ltd., Q1 2016 Earnings Call, Jul 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2267:JP ¥6,210.00 JPY -200.00

2267 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 5,004 INR +292.10
BioGaia AB kr270.00 SEK -6.50
Biostime International Holdings Ltd $12.30 HKD -0.02
Mead Johnson Nutrition Co $76.73 USD +0.69
View Industry Companies
 

Industry Analysis

2267

Industry Average

Valuation 2267 Industry Range
Price/Earnings 38.1x
Price/Sales 2.9x
Price/Book 3.3x
Price/Cash Flow 40.5x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YAKULT HONSHA CO LTD, please visit www.yakult.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.